Many colorectal cancers (CRCs) develop in genetically susceptible individuals most of whom are not carriers of germ line mismatch repair or APC gene mutations and much of the heritable risk of CRC appears to be attributable to the co-inheritance of multiple low-risk variants. The accumulated experience to date in identifying this class of susceptibility allele has highlighted the need to conduct statistically and methodologically rigorous studies and the need for the multi-centre collaboration. This has been the motivation for establishing the COGENT (COlorectal cancer GENeTics) consortium which now includes over 20 research groups in Europe, Australia, the Americas, China and Japan actively working on CRC genetics. Here, we review the rationale for identifying lowpenetrance variants for CRC and the current and future challenges for COGENT.
Background
Many colorectal cancers (CRCs) develop in genetically susceptible individuals most of whom are not carriers of germ line mismatch repair or APC gene mutations and much of the heritable risk of CRC is thought to be the consequence of the co-inheritance of multiple low-risk variants (1) (2) (3) . Recent genome-wide association (GWA) studies have vindicated this hypothesis identifying single-nucleotide polymorphisms (SNPs) localizing to multiple chromosomal regions which influence CRC risk (4) (5) (6) (7) (8) (9) (10) (11) . While the risk of CRC associated with each of the variants is individually modest, taken together, they could make a significant contribution to disease burden by virtue of their high frequencies in the population.
As well as establishing a role for genetic susceptibility in the development of CRC, these data provide novel insight into disease causation; notably a number of risk variants annotate genes encoding components of the transforming growth factorbeta superfamily signaling pathway (4, 10, 11 ). An important long-term outcome of such GWA studies of CRC is that the knowledge gained about the underlying molecular basis of CRC may lead to the development of innovative therapeutic and preventative measures.
It is apparent that the successful identification of low-risk variants for CRC is contingent on having access to large casecontrol sample sets, something only realistically achievable through multicentre collaboration. This has been the motivation for establishing the COGENT (COlorectal cancer GENeTics) consortium (12) . Here, we review the current state of knowledge regarding low-penetrance susceptibility to CRC and the opportunities for COGENT researchers to identify novel CRC predisposition genes.
Characteristics of low-penetrance variants and implications for discovery
In recent years, the introduction of the Human Genome Project and other international initiatives has allowed detailed examination of the entire genetic code. This information led to the development of comprehensive sets of tagging SNPs that capture a high proportion of common genetic variation. This coupled with the advent of high-throughput analytical platforms capable of simultaneously genotyping hundreds of thousands of SNPs heralded the advent of GWA studies. The GWA approach is agnostic in that it does not depend upon prior knowledge of function or presumptive involvement of any gene in disease causation.
The GWA studies of CRC that have been performed so far have reported SNPs at 14 independent genetic loci conclusively associated with CRC risk: 1q41 (4), 3q26.2 (4), 8q23.1 (EIF3H) (6), 8q24.21 (5,7), 10p14 (6), 11q23 (8,13), 12q13.13 (4), 14q22.2 (BMP4) (9), 15q13.3 (GREM1) (10), 16q22.1 (CDH1) (9), 18q21.1 (SMAD7) (11), 19q13.1 (RHPN2) (9), 20p12.3 (9) and 20q13.33 (LAMA5) (4) ( Table 1 ). Data from these GWA studies are proving to be highly informative regarding the allelic architecture of CRC susceptibility. Firstly, the CRC risks associated with each of the variants at each of these loci are at best modest (relative risks of 1.1-1.3). Secondly, while there is little evidence of interactive effects between loci, the distribution of risk alleles follows a normal distribution in both CRC cases and controls, with a shift towards a higher number of risk alleles in affected individuals, consistent with a polygenic model of disease predisposition ( Figure 1) . Hence, by acting in concert, a small proportion of the population which carry a large number of risk alleles can have $3-fold increase in risk compared to those with the median number of risk alleles. Thirdly, few common variants account for .1% of inherited risk and only a small proportion of the heritability of CRC can be explained by the currently identified loci. Fourthly, multiple functional variants can localise to the same chromosomal region, including low frequency variants with significantly larger effects on CRC risk. Finally, most of the loci map to regions bereft of genes or protein-encoding transcripts. Hence, it is likely that much of the common variation in CRC risk is mediated through sequence changes influencing gene expression, perhaps in a subtle fashion or through effects on pathway components mitigated by functional redundancy.
History of COGENT
Over a 10-year period, collaborations had been steadily developing between various researchers in the UK, Canada, the Americas, Holland, Germany, Finland, Spain and Australia that were engaged in studies of genetic susceptibility to CRC. What initially began from relatively loose affiliations centred around work on specific projects between individual groups begun to crystallise into a more formal collaborative network in 2007 with the advent of GWA studies of CRC. To continue and expand collaboration, a meeting was held at the University of Leiden, The Netherlands, in January 2009, to review the current state of ongoing association studies of CRC. There assembled an international team of researchers with expertise encompassing genetic epidemiology, statistical genetics, gene mapping, biology, molecular genetics, pathology and diagnosis and the clinical management of CRC. There was a consensus among participants that the challenges in this field of research could only be optimally addressed through international cooperative efforts and the group unanimously decided to establish the COGENT consortium (12) . An invitation to join COGENT, subsequently extended to other groups known to be engaged in association studies of CRC, was well received. Subsequent to the Leiden meeting, a number of meetings have been held under the COGENT guise, notably in Barcelona and most recently in Edinburgh. These meetings have led to the consolidation of the group and presently, over 20 research groups are actively participating in COGENT led activities.
Future directions
Prospects for identifying novel risk variants through GWAbased analyses The accumulated experience gained in conducting the GWA studies of CRC has served to highlight the difficulties in conducting statistically and methodologically rigorous association studies to identify novel CRC predisposition loci. The key issues are firstly, because of the large number of polymorphisms in the genome, false-positive associations are inevitably more frequent than true-positive associations when testing large numbers of markers even if studies are rigorously conducted; hence, associations need to attain a high level of statistical significance to be established beyond reasonable doubt. For this reason, in GWA studies, a P-value of 5.0 Â 10 À8 has been advocated as being appropriate threshold for defining genome-wide significance (15, 16) . Secondly, given that relative risks associated with variants are modest case-control studies involving just a few hundred cases and controls have very poor power to reliably identify genetic determinants conferring modest, but potentially important, risks. Thirdly, positive associations need to be replicated in independent case-control series to mitigate against Type 1 error. However, to increase power, the allelic architecture of the population from which these case-control series are ascertained needs to have similar ancestry and, ideally, the same linkage disequilibrium (LD) structure. Indeed, careful attention must be paid to population stratification as a source of confounding because cancer rates and allele frequencies vary with race/ ethnicity. Wide comparisons between the population genetics of different ethnic groups have shown that SNP allele frequencies can vary greatly between ethnic groups, principally as a result of founder effects and genetic drift. Indeed, some SNPs may be informative in one population and not in another; consequently, some CRC modifier loci may exist in some populations but not in others. Failure to account for this is likely to be the reason for many of the associations reported over the years are spurious.
The need to improve power to identify novel low-risk variants for CRC For reasons of cost efficiency, GWA studies are performed adopting a staged design, whereby the best ranked SNPs from one stage are genotyped in progressively larger datasets to attain requisite genome-wide statistical significance for associations. Figure 2 illustrates the power of a two-stage GWA study stipulating a statistical threshold of 10 À5 over the first two stages. SNPs which are truly associated at this threshold can generally be shown to be associated at 5.0 Â 10 À8 in subsequent large case-control series. Hence, power of the 
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GWA studies that have been conducted to identify common alleles conferring relative risks of !1.2 (such as the 8q24 variant) is thus high (Figure 2 ). Therefore, there are unlikely to be many additional CRC SNPs with similar effects for alleles with frequencies of .20% in populations of European ancestry. The GWA studies have, however, had limited power to detect alleles with smaller effects and/or risk allele frequencies of ,10%. By implication, variants with such profiles are likely to collectively confer substantial risk because of their multiplicity or sub-maximal LD with tagging SNPs. Hence, the current GWA-based strategies are not configured optimally to identify low frequency variants with potentially stronger effects or identify recessively acting alleles. Nor are current arrays formatted ideally to capture certain structural variants such as small scale insertions or deletions, which may impact on CRC risk. It is therefore likely that additional lowrisk variants for CRC remain to be identified by GWA studies. Ongoing GWA studies of CRC being conducted by different research groups will inevitably generate SNP data from different array platforms with different SNP representation and coverage. Using statistical methodology whereby imputation of untyped SNPs can be generated in datasets allows for harmonisation and pooled analyses to be conducted (17) . COGENT is investing heavily in efforts to expand the scale of GWA meta-analyses both in terms of sample size and SNP coverage and the number of SNPs taken forward for replication. Collectively, over 60 000 CRC cases and 57 000 controls have so far been accrued by COGENT researchers (Table II) . COGENT is extremely well equipped to meet the requirement for large-scale replication analyses necessary to identify novel risk loci.
Strategies for identifying causal variants
Data has shown that the rs69783267 (8q24) association is a direct consequence of the SNP which differentially affects TCF4 binding and has cis-regulatory effects on myc promoter activity (18, 19) . For most associations, the SNPs directly typed in GWA studies are, however, unlikely to be directly functional but are correlated with a functional variant. This is exemplified by the 8q23 and 18q24 associations which have recently shown that the SNPs are correlated with variants having allele-specific cis-effects on EIF3H and SMAD7 expression, respectively (20, 21) . Although blocks of LD allow the efficient survey of the genome, they hamper fine mapping of the disease-associated region, hence identifying the functional basis of associations is challenging. Different ethnic groups can have different LD block patterns which can be used to refine the location of a disease susceptibility locus prior to fine mapping genotyping and functional analyses. One recent development that greatly facilitates fine-mapping is the use of imputation of untyped SNPs from reference population panels which have been extensively genotyped. HapMap 2 has until recently been a major source of such reference data providing genotypes for $8 M SNPs in four main ethnicities. Initiatives such as the 1000Genomes project have recently greatly improved polymorphic annotation of the human genome harvesting $30 M SNPs thereby increasing the value of imputation.
Interactions between susceptibility alleles
It is entirely conceivable that epistatic interactions between common risk variants may exist. To the extent that they have been examined, the effects of the currently identified common low-penetrance alleles for CRC appear to be essentially independent. Such interactions are, however, difficult to detect unless marginal effects are significant, and there is also a large statistical penalty from large-scale multiple testing. It has recently been proposed that for most plausible interaction effects, a two-stage analysis has been shown to dramatically increase the power to identify interactions compared to a single-stage analysis (22) . One important implication of common susceptibility is the modification of the risks associated with high-penetrance susceptibility. Data are currently limited, but two recent studies have independently shown that 8q23.3 and 11q23.1 genotype modify CRC risk in Lynch syndrome (23, 24) .
Search for rare disease-causing variants Much of the current thinking regarding polygenic susceptibility to CRC has been dominated by the 'common-disease commonvariant' model. In addition to this class of disease susceptibility, it is essential to consider alternative models of CRC predisposition, based on rare disease causing variants. Such rare germ line variants may confer more profound effects on risk and hence have greater significance for individuals, though the population-attributable risk may be low. Examples of this class of susceptibility allele are provided by the ATM, BRIP1, PALB2 and CHEK2 variants which are detectable in 0.5-1% of many European populations and confer a 2-to 3-fold increased risk of breast cancer (25) (26) (27) (28) . In addition, as seen with MUTYH variants, alleles may act recessively and confer substantive risks of CRC (29) . While some low frequency risk alleles may be harvestable through exploitation of pre-existing GWA data, for most, the sequencing of large numbers of CRC cases will be required for their identification. Advances in sequencing technology are making an increasing feasible proposition.
Sub-group analyses
To date, most searches for CRC risk variants have been largely predicted on the assumption of CRC being a homogeneous disease. CRC, however, displays considerable heterogeneity as evidenced by differences in the spectrum of somatic mutation seen in colon and rectal cancers which is likely to reflect differences in aetiological risk factors, both environmental and inherited (30, 31) . Moreover, the molecular profiles of mismatch repair (MMR) deficient and competent cancers are distinctive and are likely to be influenced by different risk factors (31). Population-based case-control study; Ontario.
Evidence that common risk alleles can have subtype effects on CRC risk is provided by the 11q23 association which appears highly specific for rectal disease (8, 13) . While stratified analyses provide a means of teasing out important subtype specific effects, the numbers of cases in many subgroups will inevitably constraint study power. This fact further underscores the value of bringing together independent case-control series for validation analyses through initiatives such as COGENT.
Incorporating non-genetic risk factors into risk models CRC risk is undoubtedly determined by complex interactions between genetic and lifestyle/dietary risk factors. Epidemiological studies have established several dietary risk factors for colorectal neoplasia; these include low vegetable and high red meat consumption and micronutrient deficiency and excessive alcohol intake. There is a weaker association between CRC, smoking and lack of physical activity. Common genetic variants are thus likely to interact with these environmental lifestyle risk factors to modify risk. Furthermore, common variants have the potential to determine the effectiveness of chemoprevention agents such as non-steroidal anti-inflammatory drugs, hormone replacement therapy and micronutrient supplementation. In assessing the interplay between inherited and non-genetic risk factors, analyses using different population cohorts should be in theory, highly informative. At least in principle and probably in practice, some variants may have stronger or weaker effects on disease depending on environment or general genetic background as observed in inbred lines of mice. Hence, while consortia effectively permits for an increase in sample size, phenotype heterogeneity across studies represents a major obstacle potentially offsetting successful identification of gene by environment (G Â E) interactions.
Even accepting such considerations, it has, however, been questioned whether any G Â E studies are, in general, even possible, let alone worthwhile, especially given that the smaller the odds ratio, the more likely it will be that environmental factors will predominate (32) . Despite such cautionary reservations, there is considerable interest in looking for G Â E interactions, even when no main effects exist for either which is likely to generate a plethora of Type 1 errors.
Irrespective of such cautionary notes, incorporating environmental risk factor data into models of predisposition is likely to be a serious challenge. While ethnicity can be defined through genotype, environmental background is harder to standardise across studies and data harmonisation is likely to be a major obstacle to the generation of meaningful data.
Inherited prognostic and predictive variants
In addition to influencing the risk of developing CRC, inherited genetic factors may play a role in determining the natural course of the disease and its response to therapies. As a prognostic factor, the concept of germ line variation imparting inter-individual variability in tumor progression is currently receiving increasing attention for a number of cancers. Clearly, in CRC, there is a precedent for this notion as MMR status in tumours, which can be a consequence of germ line mutation, impacts on patient prognosis (33) . Furthermore, there is some evidence that SNP genotypes may be preferentially associated with specific CRC histology (24) . However, to date, there are no reliable examples of common variants influencing patient outcome from CRC. It is probably that a genetic variant affecting inter-individual disease expression will impact on later stages of clonal development rather than early events associated with an inherited susceptibility. For example, variants in growth factors or immune surveillance signalling pathways might not impact on risk of initiation but could have a substantial effect on progression or outcome of established disease. Chemotherapy response and toxicity may also be related to germ line genotype. As with conventional association studies, it is essential to impose appropriate statistical thresholds and conduct replication analyses to avoid the reporting of false positives. Linking GWA data to patient outcome provides an attractive strategy for identifying prognostic markers of outcome from CRC. It should be noted, however, that in a two-stage design for GWA studies on CRC patient' prognosis, the discovery and the validation series should be similar for phenotypes affecting prognosis. Ideally such analyses should be based on data derived from clinical trials as these patients are in receipt of standardised treatment, which may not be the case with other types of patient samples.
Concluding remarks
COGENT represents a major international collaborative study seeking to comprehensively understand the impact of inherited susceptibility to CRC and to describe the genetic landscape of the disease. The close cooperation between research groups which has been fostered will undoubtedly allow us to meet future challenges of identifying and characterising novel CRC risk alleles. The immediate goal is to work together collaboratively to study polymorphisms that have been shown to be associated with risk and to plan for future high quality biological and epidemiological studies as longer term aims. The consortium is keen to engage and have the involvement of other interested researchers and can be contacted through any of the COGENT members.
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